Fifth Third Bancorp
FDMT icon

Fifth Third Bancorp’s 4D Molecular Therapeutics FDMT Stock Holding History

Fifth Third Bancorp’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326 Buy
+35
New +$305 ﹤0.01% 4216
2025
Q3 		– Sell
-110
Closed -$408 – 2700
2025
Q2 		$408 Buy
+110
New +$387 ﹤0.01% 2505

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fifth Third Bancorp's FDMT Position: Q1 2026 in Review

Fifth Third Bancorp opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 35 shares worth $326. The stake represents ﹤0.01% of the portfolio and ranks #4216 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in FDMT as recently as Q2 2025.

Fifth Third Bancorp first reported a position in FDMT in Q2 2025 and has held it in 2 quarters since. The position peaked at $408 in Q2 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Fifth Third Bancorp held 35 shares of 4D Molecular Therapeutics worth $326 as of Q1 2026.
  • 4D Molecular Therapeutics was a new Fifth Third Bancorp position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #4216 holding.
  • Fifth Third Bancorp first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Fifth Third Bancorp's 4D Molecular Therapeutics position peaked at $408 in Q2 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.